Get the Stockscreener App
2.24
2.75%
0.06
After Hours:
2.29
0.05
+2.23%
Mereo Biopharma Group Plc Adr stock is traded at $2.24, with a volume of 915.25K.
It is up +2.75% in the last 24 hours and up +5.16% over the past month.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
See More
Previous Close:
$2.18
Open:
$2.18
24h Volume:
915.25K
Relative Volume:
0.65
Market Cap:
$1.78B
Revenue:
$10.00M
Net Income/Loss:
$-29.47M
P/E Ratio:
-11.20
EPS:
-0.2
Net Cash Flow:
$-21.55M
1W Performance:
-7.05%
1M Performance:
+5.16%
6M Performance:
-36.54%
1Y Performance:
-31.50%
1-Day Range:
$2.12
$2.265
1-Week Range:
$2.12
$2.55
52-Week Range:
$1.575
$5.02
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Name
Mereo Biopharma Group Plc Adr
Sector
Industry
Phone
4403330237300
Address
ONE CAVENDISH PLACE, LONDON
Compare MREO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
2.24 | 383.19M | 10.00M | -29.47M | -21.55M | -0.20 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Initiated | JP Morgan | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-13-23 | Resumed | BTIG Research | Buy |
| Aug-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-05-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Needham | Buy |
View All
Mereo Biopharma Group Plc Adr Stock (MREO) Latest News
Mereo BioPharma Group plc SEC 10-Q Report - TradingView
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Mereo Biopharma Group Plc ADR (MREO) can make a big difference with a little luck - Sete News
Analyzing Mereo Biopharma Group Plc ADR (MREO) After Recent Trading Activity - knoxdaily.com
How should investors view Mereo Biopharma Group Plc ADR (MREO)? - uspostnews.com
Analytical Overview: Mereo Biopharma Group Plc ADR (MREO)’s Ratios Tell a Financial Story - DWinneX
Balance Sheet Insights: Halliburton Co (HAL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
INN’s latest rating updates from top analysts. - knoxdaily.com
EVLV’s 2023 Market Dance: Down -10.63% – Time to Invest? - investchronicle.com
Mereo Biopharma Group Plc ADR: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Mereo Biopharma Group Plc ADR [MREO] Shares Fall -0.78 % on Thursday - knoxdaily.com
Brookdale Senior Living Inc [BKD] Records 50-Day SMA of $5.84 - knoxdaily.com
VST Stock Sees Surge of Approximately 7.21% in Last Five Days - knoxdaily.com
Core & Main Inc [NYSE: CNM] Sees Increase in Stock Value - knoxdaily.com
This trade activity should not be overlooked: Mereo Biopharma Group Plc ADR (MREO) - Sete News
Financial Metrics Check: B. Riley Financial Inc (RILY)’s Ratios for Trailing Twelve Months - DWinneX
Mereo Biopharma Group Plc ADR [MREO] Investment Appeal on the Rise - knoxdaily.com
Freeport-McMoRan Inc [FCX] Stock sold by Insider Robertson Maree E. for $0.58 million - knoxdaily.com
D.R. Horton Inc (DHI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Insider Sale Alert: Genworth Financial Inc [GNW] – Is it Time to sell? - knoxdaily.com
Mereo Biopharma Group Plc ADR (MREO) requires closer examination - uspostnews.com
SMX (Security Matters) Plc (SMX) shows promising results - uspostnews.com
Should investors be concerned about Uranium Energy Corp (UEC)? - uspostnews.com
Is Aquestive Therapeutics Inc (AQST) worth investing in despite its overvalued state? - uspostnews.com
Are Dave & Buster’s Entertainment Inc (PLAY) shares a good deal now? - uspostnews.com
EOLS Stock Sees Decline of Approximately -17.34% in Last Five Days - knoxdaily.com
There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News
Mereo BioPharma stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa
Mereo BioPharma stock hits 52-week low at $2.1 amid market challenges - Investing.com India
C3is Inc Inc. (CISS) Price Performance Over the Years: A Comparative Study - investchronicle.com
Microchip Technology, Inc [MCHP] Stock sold by Insider Bjornholt James Eric for $0.23 million - knoxdaily.com
Mereo BioPharma’s SWOT analysis: rare disease stock poised for breakthrough - Investing.com India
Mereo BioPharma’s SWOT analysis: rare disease stock poised for breakthrough By Investing.com - Investing.com South Africa
Mereo BioPharma stock hits 52-week low at $2.25 - Investing.com India
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights - GlobeNewswire
Mereo BioPharma Secures 3-Year Cash Runway While Pushing Phase 3 Studies Forward - Stock Titan
Closing Bell Recap: WANG & LEE Group Inc (WLGS) Ends at 0.43, Reflecting a -42.70 Downturn - The Dwinnex
Pfizer to Exit Sensodyne-Maker Haleon With Final Stake Sale - MSN
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Mereo BioPharma’s SWOT analysis: setrusumab, alvelestat drive rare disease stock potential - Investing.com India
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - Barchart
How Do Things Look For Mereo Biopharma Group Plc ADR (NASDAQ: MREO) In The Short-Term? - Stocks Register
Mereo BioPharma stock hits 52-week low at $2.52 By Investing.com - Investing.com South Africa
Mereo BioPharma stock hits 52-week low at $2.52 - Investing.com India
Prepare Yourself for Liftoff: Mereo Biopharma Group Plc ADR (MREO) - SETE News
There is no doubt that OrganiGram Holdings Inc (OGI) ticks all the boxes. - SETE News
Check Out ImmunoPrecise Antibodies Ltd (IPA)’s Trade Data Rather Than the Analysts’ Views - SETE News
Recent Insider Activity Could Benefit Mereo Biopharma Group Plc ADR (MREO) - Knox Daily
Analyzing Digital Turbine Inc (APPS) After Recent Trading Activity - Knox Daily
Market Insights: Mereo Biopharma Group Plc ADR (MREO)’s Notable Drop of -0.66, Closing at 2.99 - The Dwinnex
Mereo Biopharma Group Plc Adr Stock (MREO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mereo Biopharma Group Plc Adr Stock (MREO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scots-Knight Denise | Chief Executive Officer |
Sep 12 '24 |
Sale |
4.47 |
28,611 |
127,968 |
868,967 |
| Lewicki John A. | Chief Scientific Officer |
Sep 13 '24 |
Sale |
4.22 |
10,937 |
46,165 |
78,630 |
| Lewicki John A. | Chief Scientific Officer |
Sep 12 '24 |
Sale |
4.47 |
5,212 |
23,312 |
89,567 |
| Sermon Charles | General Counsel |
Sep 13 '24 |
Sale |
4.22 |
20,946 |
88,413 |
219,061 |
| Sermon Charles | General Counsel |
Sep 12 '24 |
Sale |
4.47 |
9,980 |
44,638 |
240,007 |
| Fox Christine Ann | Chief Financial Officer |
Sep 13 '24 |
Sale |
4.22 |
19,158 |
80,866 |
89,285 |
| Fox Christine Ann | Chief Financial Officer |
Sep 12 '24 |
Sale |
4.47 |
9,128 |
40,827 |
108,443 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 13 '24 |
Sale |
4.22 |
100,312 |
423,417 |
50,475 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 12 '24 |
Sale |
4.47 |
47,798 |
213,786 |
150,787 |
| Sermon Charles | General Counsel |
Sep 11 '24 |
Option Exercise |
0.00 |
65,600 |
0 |
249,987 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):